Viraldine sold unapproved povidone-iodine nasal and throat sprays claiming to prevent or treat COVID-19.
What happened
FDA reviewed https://viraldine.com/ on December 21, 2021, and FTC reviewed it on March 1, 2022. FDA found the site offering non-alcohol-based povidone-iodine nasal and throat antiseptics for sale in the U.S. with claims they mitigate, prevent, treat, diagnose, or cure COVID-19, including website study claims and a “4 Hour Maximum Protection” label claim.
What FDA found
The nasal and throat sprays are unapproved new drugs because no FDA-approved application is in effect and they are not generally recognized as safe and effective for their labeled uses.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The products are misbranded because they are nonprescription drugs that do not comply with section 505G and are not covered by an approved application.
section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)Labeling claims that the sprays limit or inactivate SARS-CoV-2 make them drugs intended to prevent or treat disease.
section 201(g)(1)(B)/(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(B)/(C)COVID-19 efficacy claims go beyond the general antiseptic uses allowed by the applicable OTC rules, so the products do not meet section 505G(a)(3) for marketing without approval.
section 505G(a)(3) of the FD&C Act, 21 U.S.C. 355h(a)(3)The nasal sprays are labeled for use inside the nostrils, which is not permitted under the OTC topical antiseptic rules.
1994 TFM, 59 FR 31402, as amended by 81 FR 42912The “4 Hour Maximum Protection” claim is not permitted under the OTC antiseptic rules and may give users a false sense of security.
1994 TFM, 59 FR 31402; Oral Antiseptics Proposed Rule, 59 FR 6084
What FDA wants
FDA asks the company to take immediate action to stop selling any unapproved products for COVID-19 and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the steps taken and documentation to prevent recurrence. FTC separately requires a certification within 48 hours to rcleland@ftc.gov that the unsubstantiated claims have ceased.
Who should pay attention
- online sellers of antiseptic or nasal sprays
- companies making COVID-19 prevention claims
- retailers and marketplaces listing povidone-iodine consumer products
This is a summary. Read the original letter on fda.gov.